Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bumadizone
- Development stage
- Unknown
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Bumadizone is a nonsteroidal anti-inflammatory drug (NSAID) of the carbohydrazide class, structurally related to malonic acid. It exhibits anti-inflammatory, analgesic, and antipyretic properties. Bumadizone has been approved for use in Germany and Austria for the treatment of rheumatoid arthritis and gout, as well as osteoarthritis and acute musculoskeletal pain. Its mechanism of action is typical of NSAIDs—primarily inhibition of cyclooxygenase enzyme (COX), leading to reduced synthesis of prostaglandins involved in inflammation and pain signaling[1][2][3][4][7]. The drug is administered orally, often as its calcium salt form.
- Other names
- bumadizonabumazidoneBumadizonum
02
Targets
PGHS-1 (Prostaglandin G/H Synthase 1)
Beyond the preview
Go deeper on bumadizone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bumadizone.